关于“中药治疗”的报告
艾媒咨询｜2024年中国养生茶饮行业现状研究及消费者洞察报告
国民健康需求的升级、养生文化的盛行、国家政策的支持与法令法规的准允，为药食同源产业的蓬勃发展提供了有力保障，也为养生茶饮的市场扩容注入了强劲动力。养生茶饮作为健康食疗的一种，结合了拥有数千年的历史底蕴与广大的群众基础的传统中医养生文化，被赋予着“寓医于食”的温和而个性化的天然优势。随着现代生活节奏加快和健康观念普及，养生茶饮成为了健康生活的新宠。全球新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2024年中国养生茶饮行业现状研究及消费者洞察报告》数据显示，2023年中国养生茶饮市场规模为411.6亿元，同比增长27.3%；预计2028年将突破千亿元。超九成消费者在每月养生茶饮的消费支出上超过了50元，而消费者消费养生茶饮时最重视的因素为口感与口味，其比例为65.2%。在消费群体年轻化已成趋势、健康理念成消费升级新需求的大背景下，养生茶饮企业需加强产品创新与技术升级为产业提质升级，并扩宽渠道可能，同时努力开拓年轻化的健康消费市场，创新传承中医养生文化来迎合市场需求，方可扩大市场影响力，抓住赛道机遇。
The enhancement of national healthcare needs, the promotion of health culture, the backing of national policies and the enactment of laws and regulations provide a robust assurance for the dynamic growth of the pharmaceutical and food industry, as well as inject a powerful impetus for the market expansion of healthy herbal beverage industry. Healthy herbal beverage, as a form of nutritious diet, integrates traditional Chinese medicine health culture with millennia-old history and broad public support, and is endowed with the gentle and personalized natural advantages of "integrating medicine into food". With the accelerated pace of modern life and widespread adoption of health concepts, healthy herbal beverage has emerged as a new favorite in healthy living.According to the latest Research Report 2024 China Health Herbal Beverage Industry Status Research and Consumer Insight Report released by iiMedia Research, a third-party data mining and analysis institution of the global new economy industry, China's healthy herbal beverage market size is projected to reach 41.16 billion yuan by 2023, representing a 27.3% increase. It is expected to surpass 100 billion yuan by 2028. Over 90% consumers spend more than 50 yuan per month on healthy herbal beverages, with taste being cited as the most important factor at 65.2%. Against this backdrop where younger consumer groups are gaining prominence and wellness concepts are driving consumption upgrades, healthy herbal beverage companies need to bolster product innovation and technological advancement to enhance quality while expanding potential channels. Simultaneously they should strive to tap into the younger demographic's interest in wellness products through innovative approaches that uphold traditional Chinese medicine culture in order to meet market demand effectively expand their influence.-
-
-
-
艾媒咨询|2021-2022年中国医美器械产业运行及投资决策分析报告
本报告研究涉及企业/品牌/案例：科医人，复星医药，奇致激光，半岛医疗
伴随着医美市场规模的持续扩大，中国医美器械行业发展前景可期。数据显示，预计2021年中国医美器械市场规模将超过500亿元，同比增长27.8%。从细分赛道来看，近年来，微创和无创已逐渐成为医疗美容的趋势，这就推动了以激光、超声波等能量源为代表的光电类医美器械的发展。从市场格局来看，中国正规医美机构设备的市场份额80%是进口品牌，且中高端市场被飞顿、塞诺龙等海外龙头企业占领。为了改变这一局面，国家及地方先后出台政策鼓励本土医美器械品牌的发展，同时，国有品牌也通过加大自主研发投入和投资并购来扩大市场份额，未来随着下游扩张、需求渗透、技术更新等因素有望加速进口替代。
With the continuous expansion of the medical beauty market, the development prospect of the medical beauty equipment industry in China is promising. According to the data, it is estimated that in 2021, the market size of medical devices in China will exceed 50 billion yuan, with a year-on-year growth of 27.8%. From the perspective of subdivision, in recent years, minimally invasive and non-invasive have gradually become the trend of medical beauty, which promotes the development of photoelectric medical beauty devices represented by laser, ultrasonic and other energy sources. From the perspective of market structure, 80% of the market share of China's regular medical and beauty institutions' equipment is imported brands, and the medium and high-end market is occupied by overseas leading enterprises such as feton and sinolon. In order to change this situation, the state and local governments have successively issued policies to encourage the development of local medical and beauty equipment brands. At the same time, the state-owned brands also expand their market share by increasing independent R & D investment and investment in M & A. in the future, with the downstream expansion, demand penetration, technology update and other factors, it is expected to accelerate the import substitution. -
艾媒咨询|2020年第三季度中国中药材行业数据监测季度报告
本报告研究涉及企业/品牌/案例：同仁堂、香雪制药、白云山。
数据显示，2020年第三季度，中药材价格指数迎来上涨周期。艾媒咨询分析师认为，受动物类等少数品种拉动影响，预计2020年10-11月中药材指数会持续走高，但是在12月维稳。据调查，绝大多数商户将会在2021年密切关注行业相关政策、谨慎经营，采取减少压货炒作等经营方式。因而，预计中药材市场在2020年末旺季会有一波行情的走高，但随着旺季结束，明年年初的价格会重新回落，随着疫情的常态化，中药材市场行情预期会呈周期性波动的态势。
Data show that in the third quarter of 2020, Chinese Herbal Medicine Price Index ushered in an upward cycle. iiMedia Research believe that by a small number of animals and other species pull the impact of October 2020-november Chinese herbal medicine index is expected to continue to rise, but stable in December. According to the survey, the vast majority of businesses in the 2021 will pay close attention to industry-related policies, prudent management, to reduce speculation and other business practices. As a result, the Chinese herbal medicine market is expected to see a wave of rising prices in the peak season at the end of 2020. However, as the peak season ends, prices will fall back early next year, and as the epidemic becomes more normal, chinese medicinal materials market is expected to be cyclical fluctuations in the situation. -
艾媒咨询|2020Q2中国中药材行业季度数据监测报告
本报告研究涉及企业/品牌/案例：云南白药，天士力。
数据显示，2020年4-5月中药材价格指数小幅下降，行情总体较为震荡。艾媒咨询分析师认为，自第二季度起中药材基本不受新冠肺炎疫情影响，市场秩序趋于稳定，但需求仍然不足，中药材基本以减产居多，减产的信号给予商家部分信心，一旦消费情况好转，中药材价格会重新上涨，因此商家谨慎投资与积极备货双管齐下，导致第二季度中药材大盘指数震荡。
Data show that the price index of Chinese medicinal materials declined slightly from April to May 2020, and the market was generally volatile. iiMedia Research believe that since the second quarter, Chinese herbal medicines have basically not been affected by the new coronary pneumonia epidemic. The market order has stabilized, but demand is still insufficient. Basically, Chinese herbal medicines basically reduce production. The signal of reduced production gives businesses some confidence. Once consumed The situation improves, and the prices of Chinese herbal medicines will rise again. Therefore, merchants' cautious investment and active inventory preparation have taken two measures, leading to the second quarter Chinese herbal medicines market index shock. -
艾媒咨询|2020年中国细胞生物产业和商业应用分析报告
本报告研究涉及企业/品牌/案例：华夏源、复星医药。
中国细胞生物产业类型呈现多样化趋势，细胞生物临床研究不断深化，伴随生态合作的拓展将进一步加速细胞生物产业生态圈的形成，生态圈的完善将在很大限度上推动产业快速发展。数据显示，中国细胞治疗企业融资金额不断增加，从2014年的0.2亿元增长至2019年的28.9亿元。其中，2018年中国细胞治疗企业融资额同比增长706.8%，呈现迅猛发展态势。未来中国细胞生物产业的发展将充满机遇，同时也有挑战并存。后续产业的发展，将在5G、人工智能等新技术应用下加速升级。面临多端变化的市场格局，企业也应积极开展生态合作以及更为密切关注市场需求动向，将疗法和新一代医疗创新技术深度融合，实现市场产品多元化与差异化，并推出独特性的精准治疗，从而最大限度地释放产业价值。
The types of cell biological industry in China show a trend of diversification, and the deepening of cell biological clinical research will further accelerate the formation of the cell biological industry ecosystem with the expansion of ecological cooperation, and the improvement of the ecosystem will promote the rapid development of the industry to a large extent. Data show that the financing amount of Chinese cell therapy enterprises keeps increasing, from 20 million yuan in 2014 to 2.89 billion yuan in 2019. Among them, in 2018, the financing amount of Chinese cell therapy enterprises increased by 706.8% year on year, showing a rapid development trend. In the future, the development of China's cell biology industry will be full of opportunities and challenges. The development of subsequent industries will be accelerated with the application of new technologies such as 5G and ARTIFICIAL intelligence. In the face of the changing market pattern, enterprises should also actively carry out ecological cooperation and pay close attention to the trend of market demand, deeply integrate therapy and new-generation medical innovation technology, realize the diversification and differentiation of market products, and launch unique precision therapy, so as to maximize the release of industrial value. -
艾媒报告|2019-2021年中国中药材行业发展现状及产业链分析报告
本报告研究涉及企业/品牌/案例：白云山,同仁堂,云南白药,昆明制药,华润三九,天士力,央视财经,牛黄,薏仁,茯苓,黄芪,川芎,片仔癀,中国中药,紫鑫药业,九洲药业,陇神戎发,众生药业,通化金马,江中药业,寿仙谷,新天药业,盘龙药业,佛慈制药,昆药集团,香雪制药,六味地黄丸,人参养荣丸,四神丸,白蚀丸,血脂康胶囊,茵栀黄口服液,一捻金胶囊,乙肝益气解郁颗粒,二十七味定坤丸,十六味冬青丸,参芪消渴胶囊,十香返生丸,华润三九,红日药业,源和药业,太龙药业,中智药业，培力控股,盛实百草,芍花堂,亳药千草,汇群中药
国内经济增长以及居民消费水平的提高都刺激着中药医疗消费需求的增长。iiMedia Research（艾媒咨询）调查显示，有49%的受访用户倾向中医药治疗，与西药基本持平。2018年中国中药材市场规模达1246亿元，同比增长22.40%，在巨大的需求驱动下，中药材种植面积扩大，药材产量将会持续增长。
中药材主要包括上游种植、养殖市场，中游流通市场和下游销售市场三大环节。目前，中药饮片和中成药生产是中药产业的核心，主要包括中药加工，包括中药配方颗粒、中药饮片加工、中成药制造等。中药饮片领域方面，行业销售收入增速分别在2016和2018年触底回升，华润三九、中国中药、红日药业等上市公司表现良好；中药配方颗粒方面，2006-2016年，中国市场销售额占饮片市场销售额比重由1.2%增加至6.0%，中药配方颗粒或将成为中药饮片加工行业应用广泛的产品；中成药方面，随着国家医改政策的推行，中成药消费需求趋于合理，中成药产量开始回落，但仍处于一个比较高的产量水平，云南白药、白云山、同仁堂、紫鑫药业等上市企业表现良好。
Chinese medicinal materials mainly include upstream planting, breeding market, midstream circulation market and downstream sales market three links. At present, the production of Chinese medicine tablets and traditional Chinese medicine is the core of the Chinese medicine industry, including the processing of Traditional Chinese medicine, including Chinese medicine formula particles, Chinese medicine tablet processing, traditional Chinese medicine manufacturing. In the field of Chinese medicine tablets, the growth rate of sales revenue in the industry rebounded in 2016 and 2018, respectively, china Resources 39, Chinese medicine, Red Day Pharmaceuticals and other listed companies performed well; Chinese medicine formula particles may become a widely used product in the Chinese medicine tablet processing industry, Chinese medicine, with the implementation of the national medical reform policy, the consumption demand of traditional Chinese medicine tends to be reasonable, the production of Traditional Chinese medicine began to fall, but still at a relatively high level of production, Yunnan White Medicine, Baiyunshan, Tongrentang, Zixin Pharmaceutical and other listed enterprises performed well. -
艾媒报告|2019-2021年中国中药材用户调研及延伸市场研究报告
本报告研究涉及企业/品牌/案例：同仁堂，片仔癀，东阿阿胶，太极集团，胡庆余堂，同仁牛黄清心丸，黄芪颗粒，雷氏丹参片，云峰气血口服液，太极五子衍宗丸，太极生力雄丸，仲景左归丸，一笑堂龟甲壳，白云山复方丹参片，天士力养血清脑颗粒，白云山夏桑菊颗粒，白云山板蓝根颗粒
随着居民消费水平的提升和健康保健意识的增强，总体健康需求在扩大，进而推动中医药市场的发展，2018年中国中药材市场规模达1246亿元，同比增长22.40%，预计到2024年，中药材市场规模将达2004亿元。
iiMedia Research（艾媒咨询）调查显示，2019年接近五成受访者购买过中药材，滋补养生和治病是购买中药材的两大目的。由于中医药应用范围广泛，中医药产业链不断扩展延伸，并加速扩展和整合。同仁堂、片仔癀、东阿阿胶等中药巨头企业纷纷布局中药材后市场，建设中药大健康产业，如植物提取物、保健食品、中药化妆品等，已成为我国生命健康产业中最具成长性的组成部分。
According to the iiMedia Research survey, nearly 50% of respondents have bought Chinese herbal medicines in 2019, and tonic sage and cure are the two main purposes for buying Chinese herbal medicines. Due to the wide range of applications of Chinese medicine, the Chinese medicine industry chain continues to expand and expand and accelerate the expansion and integration. Tongrentang, tablets, Dong'a gum and other Chinese medicine giant enterprises have laid out the chinese medicine after the market, the construction of chinese medicine large health industry, such as plant extracts, health food, Chinese medicine cosmetics, etc., has become China's life and health industry in the most growth component.
（以下为节选页，完整版共88页）
- 1
- 2
